Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to Post Q2 2022 Earnings of ($0.67) Per Share, Oppenheimer Forecasts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) – Research analysts at Oppenheimer boosted their Q2 2022 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Monday, May 2nd. Oppenheimer analyst F. Brisebois now expects that the company will post earnings per share of ($0.67) for the quarter, up from their prior estimate of ($0.71). Oppenheimer also issued estimates for Tarsus Pharmaceuticals’ Q3 2022 earnings at ($1.11) EPS, Q4 2022 earnings at ($0.78) EPS and FY2022 earnings at ($3.21) EPS.

Several other equities research analysts have also recently issued reports on the company. Zacks Investment Research upgraded Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $48.00.

Shares of NASDAQ:TARS opened at $12.92 on Thursday. The stock has a market cap of $267.56 million, a PE ratio of -17.94 and a beta of 1.44. The business has a 50 day moving average of $17.81 and a 200-day moving average of $21.17. Tarsus Pharmaceuticals has a 12-month low of $12.25 and a 12-month high of $39.08.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last issued its quarterly earnings data on Monday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $7.11 million.

Several large investors have recently made changes to their positions in the company. Citigroup Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 123.0% during the fourth quarter. Citigroup Inc. now owns 2,145 shares of the company’s stock worth $48,000 after buying an additional 1,183 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 6.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock worth $632,000 after buying an additional 1,623 shares in the last quarter. Geode Capital Management LLC increased its holdings in Tarsus Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock valued at $2,830,000 after purchasing an additional 2,117 shares during the period. State Street Corp increased its holdings in Tarsus Pharmaceuticals by 2.3% in the fourth quarter. State Street Corp now owns 129,742 shares of the company’s stock valued at $2,919,000 after purchasing an additional 2,940 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Tarsus Pharmaceuticals by 13.7% in the third quarter. Bank of New York Mellon Corp now owns 24,523 shares of the company’s stock valued at $529,000 after purchasing an additional 2,950 shares during the period. Institutional investors own 70.00% of the company’s stock.

In other Tarsus Pharmaceuticals news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of the company’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $12.67, for a total transaction of $250,080.46. Following the completion of the sale, the insider now directly owns 2,474,375 shares in the company, valued at $31,350,331.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 33.08% of the stock is owned by corporate insiders.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also